Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: A consideration of dose, core temperature and dopamine synthesis

Brain Research

Volumn 806, Issue 1, 1998, Pages 69-78

  Sabol, Karen E ^a   Seiden, Lewis S ^b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Amphetamine; Dopamine; In vivo dialysis; MDMA; Reserpine; Serotonin; Striatum; Vesicular storage

Indexed keywords

3 HYDROXYBENZYLHYDRAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; DECARBOXYLASE INHIBITOR; DEXAMPHETAMINE; DOPAMINE; RESERPINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORE TEMPERATURE; CYTOPLASM; DOPAMINE METABOLISM; DOSE RESPONSE; MALE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SYNAPSE VESICLE;

ANIMALS; BODY TEMPERATURE; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTRANSMITTER AGENTS; RATS; RATS, SPRAGUE-DAWLEY; RESERPINE; SEROTONIN AGENTS;

EID: 0032556069     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00720-3     Document Type: Article

References (26)

1. Ahlenius S., Wijkstrom A. Mixed agonist-antagonist properties of umespirone at neostriatal dopamine receptors in relation to its behavioral effects in the rat. Eur. J. Pharmacol. 222:1992;69-74.
2. Bowyer J.F., Gough B., Slikker W., Lipe G.W., Newport G.D., Holson R.R. Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats. Pharmacol. Biochem. Behav. 44:1993;87-98.
3. Braestrup C. Biochemical differentiation of amphetamine vs. methylphenidate and nomifensine in rats. J. Pharm. Pharmacol. 29:1977;463-476.
4. Butcher S.P., Fairbrother I.S., Kelly J.S., Arbuthnott G.W. Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study. J. Neurochem. 50:1988;346-355.
5. Cadoni C., Pinna A., Russi G., Consolo S., Di Chiara G. Role of vesicular dopamine in the in vivo stimulation of striatal dopamine transmission by amphetamine: evidence from microdialysis and Fos immunohistochemistry. Neuroscience. 65:1995;1027-1039.
6. Callaway C.W., Kuczenski R., Segal D.S. Reserpine enhances amphetamine stereotypies without increasing amphetamine-induced changes in striatal dialysate dopamine. Brain Res. 505:1989;83-90.
7. Danielson T.J., Coutts R.T., Coutts K.A., Keashly R., Tang A. Reserpine-induced hypothermia and its reversal by dopamine agonists. Life Sciences. 37:1985;31-38.
8. Fischer J.F., Cho A.K. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther. 208:1979;203-209.
9. Florin S.M., Kuczenski R., Segal D.S. Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral considerations. J. Pharmacol. Exp. Ther. 274:1995;231-241.
10. Heeringa M.J., Abercrombie E.D. Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release. J. Neurochem. 65:1995;192-200.
11. Johnson R.G. Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. Physiol. Rev. 68:1988;232-307.
12. L.H. Koopmans, An Introduction to Contemporary Statistics, Duxbury Press, Belmont, CA, 1981.
13. 3H] dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine Biochem. Pharmacol. 31:1982;983-992.
14. Niddam R., Arbilla S., Scatton B., Dennis T., Langer S.Z. Amphetamine induced release of endogenous dopamine in vitro is not reduced following pretreatment with reserpine. Naunyn-Schmiedeberg's Arch. Pharmacol. 329:1985;123-127.
15. Parker E.M., Cubeddu L.X. Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J. Pharmacol. Exp. Ther. 245:1988;199-210.
16. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, Orlando, FL, 1986.
17. A. Philippu, H. Matthaei, Transport and storage of catecholamines in vesicles, in: U. Trendelenburg, N. Weiner (Eds.), Catecholamines I, Springer, New York, 1988, pp. 1-42.
18. Rudnick G., Wall S.C. The molecular mechanism of 'ecstasy' [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. U.S.A. 89:1992;1817-1821.
19. Scheel-Kruger J. Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain. Eur. J. Pharmacol. 14:1971;47-59.
20. Seiden L.S., Sabol K.E., Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. Annual Review of Pharmacology and Toxicology. 32:1993;639-677.
21. Sulzer D., Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron. 5:1990;797-808.
22. Sulzer D., St. Remy C., Rayport S. Reserpine inhibits amphetamine action in ventral midbrain culture. Mol. Pharmacol. 49:1996;338-342.
23. Tissari A.H. Increase of dopamine synthesis in synaptosomes from rats treated with neuroleptics or reserpine. Med. Biol. 60:1982;38-41.
24. 3H ]amphetamine with rat brain synaptosomes: II. Active transport J. Pharmacol. Exp. Ther. 257:1991;830-835.
25. 3H ]amphetamine with rat brain synaptosomes: I. Saturable sequestration J. Pharmacol. Exp. Ther. 257:1991;820-829.
26. Zetterstrom T., Sharp T., Ungerstedt U. Further evaluation of the mechanism by which amphetamine reduces striatal dopamine metabolism: a brain dialysis study. Eur. J. Pharmacol. 132:1986;1-9.